Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open Label, Multicenter, Randomized Study to Assess the Efficacy and Safety of Mizoribine in Active Rheumatoid Arthritis Patients Unsuccessfully Treated With Disease-modifying Antirheumatic Drug

Trial Profile

Open Label, Multicenter, Randomized Study to Assess the Efficacy and Safety of Mizoribine in Active Rheumatoid Arthritis Patients Unsuccessfully Treated With Disease-modifying Antirheumatic Drug

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mizoribine (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms AMOLED
  • Sponsors Chong Kun Dang
  • Most Recent Events

    • 25 Jun 2015 Planned End Date changed from 1 Jun 2015 to 1 Oct 2016 as reported by ClinicalTrials.gov.
    • 25 Jun 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov.
    • 25 Jun 2015 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top